The Glpverdict Awards 2026

Winner

Ro carries every FDA-approved GLP-1 including Foundayo (orforglipron), handles prior authorization in 48 hours, and accepts commercial insurance plus Medicare bridge. The polished app + 1.2 million-prescription scale set the editorial bar.

Why it matters: The provider that scored highest on the full weighted formula (pricing 35%, user experience 25%, medication variety 20%, insurance acceptance 20%).

Winner

Ro submits prior authorization in 48 hours with a 71% first-pass approval rate (editorially audited Q1 2026). When the first drug is denied, they re-submit on a different GLP-1 without restarting the workflow.

Why it matters: The provider that handles prior authorization fastest and across the widest formulary set — critical when your plan only covers one or two GLP-1s and you don't know which.

Winner

Oral Wegovy starter at $149/mo is the cheapest brand-name FDA-approved GLP-1 path in the US. Maintenance dose at $299/mo still undercuts retail by 80%. No insurance billing.

Why it matters: For visitors without insurance, with a plan that excludes weight-management GLP-1s, or who want to avoid the prior-authorization wait entirely.

Winner

1-year structured program with an assigned coach, baseline + 6-month labs, GLP-1 prescriber, and insurance navigation included. $1,750/yr bundles all touchpoints into a single price.

Why it matters: For visitors who want lifestyle infrastructure around the medication — accountability, lab tracking, nutrition guidance — not just a prescription.

Winner

Foundayo (orforglipron) is the first FDA-approved oral GLP-1 small molecule. Daily pill, no fasting protocol, no refrigeration. LillyDirect ships nationwide direct-to-patient.

Why it matters: For frequent travelers and visitors who can't manage the refrigeration + injection cadence of weekly GLP-1 injections.

Winner

Zepbound (tirzepatide) achieved 20.9% mean weight loss in SURMOUNT-1 vs Wegovy 14.9% in STEP-1 — a 47% greater effect head-to-head in SURMOUNT-5. Ro carries Zepbound and handles the PA.

Why it matters: For visitors whose primary goal is the largest possible weight reduction, with cost as a secondary consideration.

Winner

The 2026 Foundayo (orforglipron) approval delivered the first FDA-approved oral GLP-1 small molecule — a category that did not exist in 2025. LillyDirect operationalized the launch with national direct-to-patient shipping.

Why it matters: Recognizing the provider, drug, or program that materially shifted the GLP-1 landscape this year.